

Supplementary Information

Asymmetric synthesis of CF₃- and indole-containing tetrahydro-β-carbolines via chiral spirocyclic phosphoric acid-catalyzed *aza*-Friedel-Crafts reaction

En Xie, Abdul Rahman and Xufeng Lin
Email:lxfock@zju.edu.cn.


Table of Contents:

1. General Remarks.....	S2
2. General Procedure for Synthesis of Dihydro-β-carbolines	S2
3. General Procedure for Asymmetric <i>aza</i> -Friedel-Crafts Reaction.....	S4
4. References.....	S11
5. Copies of NMR and HPLC for Compounds.....	S12


1. General Remarks

All reactions were carried out in oven-dried glassware with magnetic stirring under a nitrogen atmosphere unless otherwise mentioned. All solvents were purified and dried according to standard methods prior to use. ^1H NMR spectra were recorded on 400 MHz spectrometer. The chemical shifts were reported relative to internal standard TMS (0) in CDCl_3 or 2.5 in DMSO-d_6 . The following abbreviations were used to describe peak patterns where appropriate: br=broad, s=singlet, d=doublet, t=triplet, q=quartet, m=multiplet. Coupling constants were reported in Hertz (Hz). ^{13}C NMR spectra were recorded on 100 MHz spectrometer, referred to the internal solvent signals (77.0 for CDCl_3 or 40.0 for DMSO-d_6). ^{19}F NMR spectra were recorded on 376 MHz in CDCl_3 . Infrared spectra were recorded on an ATR-FTIR spectrometer. HRMS were obtained using EI ionization. Optical rotations were determined using a Perkin Elmer Model 341 polarimeter at 20 °C. Enantiomeric excesses (ee) were determined by chiral high-performance liquid chromatography. HPLC analysis was performed using Chiralcel columns (Chiralcel OD-H, AD-H and Chiralpak OOG-4457-EO). Analytical grade solvents for the column chromatography were used as received. The chiral spirocyclic phosphoric acid catalysts were prepared according to the literatures.^{1,2}

2. General Procedure for Synthesis of Dihydro- β -carbolines



To a solution of tryptamine (15 mmol, 1.0 eq.), 4-dimethylaminopyridine (DMAP, 91.5 mg, 0.75 mmol, 0.05 eq.) in dichloromethane (30 mL) was added dropwise trifluoroacetic anhydride (2.5 mL, 18 mmol, 1.2 eq.). The resulting mixture was stirred for 2 h at room temperature in the air. After the reaction was complete, the reaction mixture was washed with saturated brine (30 mL) and extracted with dichloromethane (3x20 mL). The organic layers were dried by anhydrous Na_2SO_4 and concentrated in vacuo. Purification of the residue by flash column chromatography (petroleum ether/ethyl acetate = 6/1) afforded the desired trifluoroacetamide compound.



To a solution of the trifluoroacetamide compounds (10.9 mmol, 1.0 eq.) in toluene (50 mL) was

added phosphorus oxychloride (6.6 mL, 54.5 mmol, 5.0 eq.), trifluoromethanesulfonic acid (1.9 mL, 22 mmol, 2.0 eq.) via syringe in the ice bath. The resulting mixture was refluxed for 5 h under a nitrogen atmosphere. Upon completion the reaction mixture was allowed to cool to room temperature and quenched with water. The pH of aqueous layer was adjusted by the addition sodium hydroxide to pH 10. The resulting solution was extracted four times with EtOAc. Organic layer was washed with brine, dried over anhydrous Na₂SO₄, and solvent was removed in vacuo. Purification of the residue by flash column chromatography (petroleum ether/ethyl acetate = 6/1) afforded the 6-substituted 1-trifluoromethyl-3,4-dihydro-β-carboline **1**.

3,4-dihydro-β-carboline and 1-phenyl-3,4-dihydro-β-carboline were prepared according to the literatures.^{3,4}


1-(trifluoromethyl)-4,9-dihydro-3H-pyrido[3,4-b]indole (1a): 2.5 g, 71% over yield; yellow solid; ¹H NMR (400 MHz, CDCl₃) δ 8.49 (s, 1H), 7.61 (m, 1H), 7.42 (d, *J* = 8.3 Hz, 1H), 7.35 (m, 1H), 7.19 (m, 1H), 4.14 – 4.04 (m, 2H), 2.97 (t, *J* = 2.5 Hz, 2H); ¹³C NMR (100 MHz, CDCl₃) δ 149.2 (q, *J* = 35 Hz), 137.2, 126.1, 124.8, 123.0, 121.0, 120.2, 120.0, 119.9 (q, *J* = 275 Hz), 112.3, 48.5, 18.9;

6-methyl-1-(trifluoromethyl)-4,9-dihydro-3H-pyrido[3,4-b]indole (1b): 2.1 g, 56% over yield; white solid; ¹H NMR (400 MHz, CDCl₃) δ 8.34 (s, 1H), 7.38 (s, 1H), 7.30 (d, *J* = 8.4 Hz, 1H), 7.17 (m, 1H), 4.12 – 4.00 (m, 2H), 2.98 – 2.89 (m, 2H), 2.45 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 149.2 (q, *J* = 35 Hz), 135.7, 130.4, 128.0, 125.0, 123.1, 119.6, 119.5, 119.9 (q, *J* = 275 Hz), 111.9, 48.57, 21.45, 18.89;

6-methoxy-1-(trifluoromethyl)-4,9-dihydro-3H-pyrido[3,4-b]indole (1c): 1.6 g, 39% over yield; white solid; ¹H NMR (400 MHz, CDCl₃) δ 8.37 (s, 1H), 7.31 (d, *J* = 8.9 Hz, 1H), 7.02 (m, 1H), 6.98 (d, *J* = 2.4 Hz, 1H), 4.21 – 3.98 (m, 2H), 3.87 (s, 3H), 3.03 – 2.79 (m, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 154.9, 149.0 (q, *J* = 35 Hz), 132.5, 125.1, 123.5, 119.9 (q, *J* = 275 Hz), 119.4, 117.5, 113.2, 100.4, 55.8, 48.6, 18.9;

6-chloro-1-(trifluoromethyl)-4,9-dihydro-3H-pyrido[3,4-b]indole (1d): 2.9 g, 56% over yield; yellow solid; ¹H NMR (400 MHz, CDCl₃) δ 8.52 (s, 1H), 7.58 (d, *J* = 1.8 Hz, 1H), 7.35 (d, *J* = 8.7 Hz, 1H), 7.29 (m, 1H), 4.28 – 3.92 (m, 2H), 2.94 (m, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 148.9 (q, *J* = 35 Hz), 135.4, 126.7, 126.4, 125.8, 123.9, 119.6, 119.8 (q, *J* = 275 Hz), 119.2, 113.4, 48.5, 18.6;

3. General Procedure for Asymmetric *aza*-Friedel-Crafts Reaction



To a solution of 1-trifluoromethyl-3,4-dihydro- β -carboline **1** (0.05 mmol), indoles **2** (0.06 mmol) in toluene (1 mL) was added catalyst (*S*)-**4a** (0.0025 mmol). The resulting mixture was stirred for the indicated time at ice bath (or at room temperature) under a nitrogen atmosphere. After the reaction was complete, the reaction mixture was then subjected to a silica gel column (petroleum ether/ethyl acetate = 6/1) to afford the desired products (*S*)-**3**.

For scalable preparation of **3e:** To a solution of 1-trifluoromethyl-3,4-dihydro- β -carboline **1** (5.88 mmol, 1.4 g), 7-methyl-indole **2e** (7.06 mmol, 0.8 g) in toluene (25 mL) was added catalyst (*S*)-**4a** (0.29 mmol). The resulting mixture was stirred for 48 h at 0 °C under a nitrogen atmosphere. After the reaction was complete, the reaction mixture was quenched with aq.NaHCO₃ and extracted with toluene. The organic layer was washed with brine, dried over Na₂SO₄ and filtrated. After the solvent was removed under reduced pressure, the residue was then subjected to a silica gel column (petroleum ether/ethyl acetate) to afford the desired product **3e** (1.78g, 82% yield, 92% ee). After one recrystallization from EA-Hexane, **3e** was obtained in 70% yield with 95% ee.

(*S*)-(−)-1-(1H-indol-3-yl)-1-(trifluoromethyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole (3a): 14 mg, 81% yield; white solid; m.p. 189–190°C; 86% ee; HPLC analysis: Chiraldak AD-H (hexane/i-PrOH = 80/20, 0.8 mL/min), t_R (major) 13.048 min, t_R (minor) 18.997 min; [α]_D²⁰ = -88.1 (c 0.5, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 8.14 (s, 1H), 8.04 (s, 1H), 7.63 (d, *J* = 7.7 Hz, 1H), 7.87 – 7.25 (m, 2H), 7.23 (d, *J* = 8.3 Hz, 1H), 7.21 – 7.11 (m, 4H), 6.95 (t, *J* = 7.4 Hz, 1H), 3.39 – 3.30 (m, 1H), 3.21 – 3.10 (m, 1H), 3.00 – 2.89 (m, 1H), 2.89 – 2.77 (m, 1H), 2.12 (s, 1H); ¹⁹F NMR (376 MHz, CDCl₃) δ -72.51 (d, *J* = 5.6 Hz); ¹³C NMR (100 MHz, CDCl₃) δ 136.3, 135.9, 128.9, 126.9 (q, *J* = 285 Hz), 126.5, 125.1, 124.6 (d, *J* = 2.3 Hz), 122.8, 122.6, 120.5, 120.4, 119.7, 118.9, 113.3, 113.3, 113.0, 111.4, 60.3 (q, *J* = 28 Hz), 40.4, 22.1; IR (film): γ = 3406, 2953, 2924, 2853, 1457, 1338, 1277, 1245, 1158, 1112, 1013, 903, 744 cm⁻¹; HRMS (EI-TOF): calcd for C₂₀H₁₆F₃N₃ 355.1296, found 355.1295.

(*S*)-(−)-1-(7-chloro-1H-indol-3-yl)-1-(trifluoromethyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole (3b):

ndole (3b): 12 mg, 65% yield; yellow solid; m.p. 206-207°C; 91% ee; HPLC analysis: Chiralpak AD-H (hexane/i-PrOH = 90/10, 0.8 mL/min), t_R (major) 28.824 min, t_R (minor) 32.785 min; $[\alpha]_D^{20} = -67$ (*c* 0.2, CH_2Cl_2); ^1H NMR (400 MHz, CDCl_3) δ 8.41 (s, 1H), 8.01 (s, 1H), 7.63 (d, *J* = 7.7 Hz, 1H), 7.36 – 7.27 (m, 2H), 7.26 – 7.21 (m, 1H), 7.20 – 7.13 (m, 3H), 6.90 (t, *J* = 7.9 Hz, 1H), 6.90 (t, *J* = 7.9 Hz, 1H), 3.43 – 3.31 (m, 1H), 3.21 – 3.11 (m, 1H), 3.01 – 2.91 (m, 1H), 2.91 – 2.80 (m, 1H), 1.62 (s, 1H); ^{19}F NMR (376 MHz, CDCl_3) δ -72.71 (s, 3F); ^{13}C NMR (100 MHz, CDCl_3) δ 135.9, 133.6, 128.6, 126.6, 126.7 (q, *J* = 285 Hz), 126.5, 125.1 (d, *J* = 2.3 Hz), 122.9, 122.0, 121.3, 119.8, 119.4, 118.9, 116.8, 114.7, 113.1, 111.4, 60.4 (q, *J* = 28 Hz), 40.2, 22.1; IR (film): γ = 3409, 1489, 1340, 1318, 1233, 1179, 1083, 1056, 933, 833, 750, 731 cm^{-1} ; HRMS (EI-TOF): calcd for $\text{C}_{20}\text{H}_{15}\text{ClF}_3\text{N}_3$ 389.0907, found 389.0906.

(S)-(-)-1-(5-bromo-1H-indol-3-yl)-1-(trifluoromethyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole (3c): 17 mg, 79% yield; white solid; m.p. 225-226°C; 80% ee; HPLC analysis: Chiralpak AD-H (hexane/i-PrOH = 80/20, 0.8 mL/min), t_R (major) 13.049 min, t_R (minor) 19.619 min; $[\alpha]_D^{20} = -110.3$ (*c* 0.4, CH_2Cl_2); ^1H NMR (400 MHz, CDCl_3) δ 8.20 (s, 1H), 8.07 (s, 1H), 7.69 (s, 1H), 7.61 (d, *J* = 7.8 Hz, 1H), 7.36 (d, *J* = 8.1 Hz, 1H), 7.29 – 7.24 (m, 3H), 7.24 – 7.20 (m, 1H), 7.20 – 7.14 (m, 1H), 7.12 (d, *J* = 2.6 Hz, 1H), 3.41 – 3.28 (m, 1H), 3.16 – 3.04 (m, 1H), 2.99 – 2.87 (m, 1H), 2.85 – 2.75 (m, 1H), 1.85 (s, 1H); ^{19}F NMR (376 MHz, CDCl_3) δ -73.05 (s, 3F); ^{13}C NMR (100 MHz, CDCl_3) δ 135.8, 135.1, 128.8, 126.8, 126.7 (q, *J* = 285 Hz), 126.6, 126.1 (d, *J* = 1.4 Hz), 125.7, 123.9 (d, *J* = 1.9 Hz), 123.0, 119.8, 118.9, 113.8, 113.5, 113.0, 112.7, 111.3, 60.7 (q, *J* = 28 Hz), 40.0, 22.1; IR (film): γ = 3411, 2956, 2925, 2852, 1457, 1409, 1290, 1247, 1156, 1114, 1012, 885, 799, 745, 727 cm^{-1} ; HRMS (EI-TOF): calcd for $\text{C}_{20}\text{H}_{15}\text{BrF}_3\text{N}_3$ 433.0401, found 433.0398.

(S)-(-)-1-(7-methoxy-1H-indol-3-yl)-1-(trifluoromethyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole (3d): 14 mg, 75% yield; gray solid; m.p. 217-218°C; 75% ee; HPLC analysis: Chiralpak AD-H (hexane/i-PrOH = 80/20, 0.8 mL/min), t_R (major) 17.276 min, t_R (minor) 22.935 min; $[\alpha]_D^{20} = -40.3$ (*c* 0.67, CH_2Cl_2); ^1H NMR (400 MHz, CDCl_3) δ 8.46 (s, 1H), 8.04 (s, 1H), 7.62 (d, *J* = 7.7 Hz, 1H), 7.28 (d, *J* = 7.8 Hz, 1H), 7.23 – 7.18 (m, 1H), 7.18 – 7.13 (m, 2H), 6.86 (t, *J* = 8.0 Hz, 1H), 6.75 (d, *J* = 8.2 Hz, 1H), 6.58 (d, *J* = 7.6 Hz, 1H), 3.91 (s, 3H), 3.42 – 3.27 (m, 1H), 3.21 – 3.10 (m, 1H), 3.00 – 2.89 (m, 1H), 2.89 – 2.78 (m, 1H), 2.20 (s, 1H); ^{19}F NMR (376 MHz, CDCl_3) δ -72.60 (s, 3F); ^{13}C NMR (100 MHz, CDCl_3) δ 146.1, 135.9, 128.9, 127.0, 126.9 (q, *J* = 285 Hz),

126.6, 126.4, 124.1 (d, J = 2.5 Hz), 122.7, 120.9, 119.6, 118.9, 113.8, 113.0, 112.9, 111.4, 102.2, 60.3 (q, J = 28 Hz), 55.3, 40.3, 22.1; IR (film): γ = 3408, 2955, 2925, 2853, 1579, 1499, 1455, 1367, 1263, 1159, 1102, 1051, 1013, 903, 783, 733 cm^{-1} ; HRMS (EI-TOF): calcd for $\text{C}_{21}\text{H}_{18}\text{F}_3\text{N}_3\text{O}$ 385.1402, found 385.1401.

(S)-(-)-1-(7-methyl-1H-indol-3-yl)-1-(trifluoromethyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole (3e): 15 mg, 80% yield; white solid; m.p. 120-121°C; 92% ee; HPLC analysis: Chiralpak AD-H (hexane/i-PrOH = 80/20, 0.8 mL/min), t_R (major) 11.280 min, t_R (minor) 14.278 min; $[\alpha]_D^{20}$ = -107.1 (c 0.7, CH_2Cl_2); ^1H NMR (400 MHz, CDCl_3) δ 8.08 (s, 1H), 8.02 (s, 1H), 7.63 (d, J = 7.7 Hz, 1H), 7.30 (d, J = 7.9 Hz, 1H), 7.27 – 7.12 (m, 3H), 7.04 (d, J = 8.1 Hz, 1H), 6.97 (d, J = 7.0 Hz, 1H), 6.92 – 6.83 (m, 1H), 3.43 – 3.28 (m, 1H), 3.24 – 3.11 (m, 1H), 3.00 – 2.90 (m, 1H), 2.90 – 2.78 (m, 1H), 2.46 (s, 3H), 2.04 (s, 1H); ^{19}F NMR (376 MHz, CDCl_3) δ -72.57 (s, 3F); ^{13}C NMR (100 MHz, CDCl_3) δ 135.9, 135.9, 128.9, 127.2 (q, J = 285 Hz), 126.6, 124.7, 124.3 (d, J = 2.5 Hz), 123.1, 122.8, 120.8, 120.5, 119.7, 118.9, 118.1, 113.9, 113.0, 111.3, 60.4 (q, J = 28 Hz), 40.4, 22.1, 16.6; IR (film): γ = 3410, 2955, 2924, 2853, 1721, 1459, 1377, 1275, 1248, 1158, 1019, 897, 733 cm^{-1} ; HRMS (EI-TOF): calcd for $\text{C}_{21}\text{H}_{18}\text{F}_3\text{N}_3$ 369.1453, found 369.1449.

(S)-(-)-1-(6-methyl-1H-indol-3-yl)-1-(trifluoromethyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole (3f): 15 mg, 81% yield; white solid; m.p. 224-225°C; 81% ee; HPLC analysis: Chiralpak AD-H (hexane/i-PrOH = 80/20, 0.8 mL/min), t_R (major) 16.709 min, t_R (minor) 27.021 min; $[\alpha]_D^{20}$ = -128 (c 0.3, CH_2Cl_2); ^1H NMR (400 MHz, CDCl_3) δ 8.03 (s, 1H), 7.62 (d, J = 7.7 Hz, 1H), 7.29 (d, J = 8.0 Hz, 1H), 7.26 – 7.13 (m, 2H), 7.11 (s, 2H), 7.06 (d, J = 8.3 Hz, 1H), 6.79 (d, J = 8.2 Hz, 1H), 3.40 – 3.27 (m, 1H), 3.22 – 3.10 (m, 1H), 3.00 – 2.88 (m, 1H), 2.88 – 2.77 (m, 1H), 2.38 (s, 3H), 2.04 (s, 1H); ^{19}F NMR (376 MHz, CDCl_3) δ -72.70 (s, 3F); ^{13}C NMR (100 MHz, CDCl_3) δ 136.8, 135.9, 132.6, 129.0, 126.9 (q, J = 285 Hz), 126.6, 124.0 (d, J = 2.3 Hz), 122.9, 122.8, 122.3, 120.1, 119.7, 118.9, 113.3, 112.9, 111.3, 111.2, 60.4 (q, J = 28 Hz), 40.3, 22.1, 21.5; IR (film): γ = 3404, 2955, 2924, 2853, 1724, 1534, 1456, 1377, 1278, 1248, 1154, 1108, 1012, 903, 805, 744 cm^{-1} ; HRMS (EI-TOF): calcd for $\text{C}_{21}\text{H}_{18}\text{F}_3\text{N}_3$ 369.1453, found 369.1449.

(S)-(-)-1-(5-methyl-1H-indol-3-yl)-1-(trifluoromethyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole (3g): 14 mg, 78% yield; yellow solid; m.p. 185-186°C; 75% ee; HPLC analysis: Chiralpak AD-H (hexane/i-PrOH = 80/20, 0.8 mL/min), t_R (major) 14.622 min, t_R (minor) 22.171 min; $[\alpha]_D^{20}$ = -205 (c 0.7, CH_2Cl_2); ^1H NMR (400 MHz, CDCl_3) δ 8.06 (s, 2H), 7.61 (d, J = 7.8 Hz, 1H), 7.31

(d, $J = 8.0$ Hz, 1H), 7.22 (t, $J = 2$ Hz, 2H), 7.19 – 7.10 (m, 2H), 7.08 (s, 1H), 7.04 – 6.95 (m, 1H), 3.38 – 3.27 (m, 1H), 3.22 – 3.08 (m, 1H), 2.99 – 2.89 (m, 1H), 2.88 – 2.73 (m, 1H), 2.28 (s, 3H), 2.21 (s, 1H); ^{19}F NMR (376 MHz, CDCl_3) δ -72.68 (s, 3F); ^{13}C NMR (100 MHz, CDCl_3) δ 135.8, 134.7, 129.7, 129.0, 126.9 (q, $J = 285$ Hz), 126.6, 125.2, 125.0, 124.2, 122.9, 122.8, 120.3, 119.7, 118.9, 112.9 (d, $J = 2.3$ Hz), 111.3, 111.0, 60.5 (q, $J = 28$ Hz), 40.3, 22.1, 21.7; IR (film): $\gamma = 3407$, 2953, 2924, 2852, 1578, 1455, 1299, 1247, 1155, 1013, 903, 798, 743, 724 cm^{-1} ; HRMS (EI-TOF): calcd for $\text{C}_{21}\text{H}_{18}\text{F}_3\text{N}_3$ 369.1453, found 369.1454.

(S)-(-)-1-(1H-indol-3-yl)-6-methoxy-1-(trifluoromethyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole (3h): 15 mg, 80% yield; gray solid; m.p. 93–94°C; 85% ee; HPLC analysis: Chiralpak AD-H (hexane/i-PrOH = 85/15, 0.5 mL/min), t_R (major) 44.965 min, t_R (minor) 53.679 min; $[\alpha]_D^{20} = -245$ (c 0.3, CH_2Cl_2); ^1H NMR (400 MHz, CDCl_3) δ 8.20 (s, 1H), 7.93 (s, 1H), 7.33 (d, $J = 8.2$ Hz, 1H), 7.23 – 7.13 (m, 4H), 7.06 (d, $J = 2.4$ Hz, 1H), 7.00 – 6.92 (m, 1H), 6.91 – 6.84 (m, 1H), 3.89 (s, 3H), 3.42 – 3.30 (m, 1H), 3.22 – 3.11 (m, 1H), 2.96 – 2.86 (m, 1H), 2.87 – 2.76 (m, 1H), 2.13 (s, 1H); ^{19}F NMR (376 MHz, CDCl_3) δ -72.63 (s, 3F); ^{13}C NMR (100 MHz, CDCl_3) δ 154.2, 136.3, 131.0, 129.7, 126.9 (q, $J = 285$ Hz), 126.9, 125.1, 124.6 (d, $J = 2.3$ Hz), 122.6, 120.5, 120.5, 113.4, 112.9, 112.7, 112.1, 111.3, 100.7, 60.4 (q, $J = 28$ Hz), 56.0, 40.3, 22.2; IR (film): $\gamma = 3407$, 2924, 2849, 1626, 1486, 1457, 1338, 1215, 1145, 1114, 1011, 903, 805, 744 cm^{-1} ; HRMS (EI-TOF): calcd for $\text{C}_{21}\text{H}_{18}\text{F}_3\text{N}_3\text{O}$ 385.1402, found 385.14018.

(S)-(-)-1-(1H-indol-3-yl)-6-methyl-1-(trifluoromethyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole (3i): 14 mg, 76% yield; white solid; m.p. 146–147°C; 86% ee; HPLC analysis: Chiralpak AD-H (hexane/i-PrOH = 85/15, 0.5 mL/min), t_R (major) 12.170 min, t_R (minor) 19.392 min; $[\alpha]_D^{20} = -105.3$ (c 0.6, CH_2Cl_2); ^1H NMR (400 MHz, CDCl_3) δ 8.15 (s, 1H), 7.95 (s, 1H), 7.41 (s, 1H), 7.31 (d, $J = 8.2$ Hz, 1H), 7.22 – 7.10 (m, 4H), 7.07 – 7.00 (m, 1H), 6.95 (t, $J = 7.6$ Hz, 1H), 3.39 – 3.28 (m, 1H), 3.19 – 3.07 (m, 1H), 2.96 – 2.86 (m, 1H), 2.86 – 2.75 (m, 1H), 2.48 (s, 3H), 1.95 (s, 1H); ^{19}F NMR (376 MHz, CDCl_3) δ -72.54 (s, 3F); ^{13}C NMR (100 MHz, CDCl_3) δ 136.3, 134.2, 129.0, 126.9 (q, $J = 285$ Hz), 126.8, 125.1, 124.6 (d, $J = 2.5$ Hz), 124.4, 122.6, 120.5, 120.5, 118.6, 113.4, 112.5, 111.3, 111.0, 60.4 (q, $J = 28$ Hz), 40.4, 22.1, 21.5; IR (film): $\gamma = 3405$, 2953, 2923, 2855, 1619, 1457, 1417, 1337, 1303, 1278, 1246, 1156, 1126, 1016, 903, 800, 745 cm^{-1} ; HRMS (EI-TOF): calcd for $\text{C}_{21}\text{H}_{18}\text{F}_3\text{N}_3$ 369.1453, found 369.1453.

(S)-(-)-6-chloro-1-(1H-indol-3-yl)-1-(trifluoromethyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole (3j): 14 mg, 72% yield; purple solid; m.p. 108-109°C; 75% ee; HPLC analysis: Chiralpak AD-H (hexane/i-PrOH = 80/20, 0.8 mL/min), t_R (major) 11.874 min, t_R (minor) 17.872 min; $[\alpha]_D^{20} = -5.4$ (c 0.9, CH_2Cl_2); ^1H NMR (400 MHz, CDCl_3) δ 8.19 (s, 1H), 8.08 (s, 1H), 7.58 (d, J = 1.7 Hz, 1H), 7.34 (d, J = 8.2 Hz, 1H), 7.23 – 7.11 (m, 4H), 7.06 (d, J = 8.1 Hz, 1H), 6.99 – 6.90 (m, 1H), 3.40 – 3.30 (m, 1H), 3.21 – 3.10 (m, 1H), 2.95 – 2.85 (m, 1H), 2.85 – 2.76 (m, 1H), 2.04 (s, 1H); ^{19}F NMR (376 MHz, CDCl_3) δ -72.41 (s, 3F); ^{13}C NMR (100 MHz, CDCl_3) δ 136.2, 134.2, 130.4, 127.6, 126.8 (q, J = 285 Hz), 125.4, 125.1, 124.4 (d, J = 2.6 Hz), 123.1, 122.7, 120.6, 120.2, 118.5, 113.0, 112.7, 112.4, 111.4, 60.2 (q, J = 28 Hz), 40.3, 21.9; IR (film): γ = 3423, 3209, 2953, 2925, 2846, 1724, 1618, 1540, 1458, 1442, 1338, 1290, 1266, 1244, 1157, 1064, 1011, 902, 799, 744 cm^{-1} ; HRMS (EI-TOF): calcd for $\text{C}_{20}\text{H}_{15}\text{ClF}_3\text{N}_3$ 389.0907, found 389.0902.

(S)-(-)-6-methoxy-1-(7-methyl-1H-indol-3-yl)-1-(trifluoromethyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole (3k): 16 mg, 82% yield; purple solid; m.p. 111-112°C; 91% ee; HPLC analysis: Chiralpak AD-H (hexane/i-PrOH = 80/20, 0.8 mL/min), t_R (major) 15.889 min, t_R (minor) 19.589 min; $[\alpha]_D^{20} = -14.7$ (c 2.2, CH_2Cl_2); ^1H NMR (400 MHz, CDCl_3) δ 8.10 (s, 1H), 7.92 (s, 1H), 7.18 (m, 2H), 7.06 (d, J = 2.4 Hz, 1H), 7.02 (d, J = 8.1 Hz, 1H), 6.96 (d, J = 7.0 Hz, 1H), 6.92 – 6.83 (m, 2H), 3.88 (s, 3H), 3.41 – 3.26 (m, 1H), 3.22 – 3.09 (m, 1H), 2.96 – 2.86 (m, 1H), 2.86 – 2.76 (m, 1H), 2.45 (s, 3H), 1.86 (s, 1H); ^{19}F NMR (376 MHz, CDCl_3) δ -72.59 (s, 3F); ^{13}C NMR (100 MHz, CDCl_3) δ 154.2, 135.9, 131.0, 129.7, 126.9 (q, J = 285 Hz), 126.9, 124.7, 124.3 (d, J = 2.6 Hz), 123.1, 120.8, 120.5, 118.1, 113.9, 112.9, 112.7, 112.1, 100.7, 60.4 (q, J = 28 Hz), 55.9, 40.4, 22.1, 16.5; IR (film): γ = 3411, 2925, 2846, 1626, 1486, 1456, 1253, 1215, 1138, 1020, 899, 784, 733 cm^{-1} ; HRMS (EI-TOF): calcd for $\text{C}_{22}\text{H}_{20}\text{F}_3\text{N}_3\text{O}$ 399.1558, found 399.1559.

(S)-(-)-6-methyl-1-(7-methyl-1H-indol-3-yl)-1-(trifluoromethyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole (3l): 16 mg, 85% yield; white solid; m.p. 106-107°C; 91% ee; HPLC analysis: Chiralpak AD-H (hexane/i-PrOH = 80/20, 0.8 mL/min), t_R (major) 12.003 min, t_R (minor) 15.484 min; $[\alpha]_D^{20} = -45.5$ (c 1, CH_2Cl_2); ^1H NMR (400 MHz, CDCl_3) δ 8.02 (s, 1H), 7.95 (s, 1H), 7.41 (s, 1H), 7.19 – 7.08 (m, 2H), 7.02 (m, 2H), 6.95 (d, J = 7.0 Hz, 1H), 6.86 (t, J = 2 Hz 1H), 3.36 – 3.26 (m, 1H), 3.16 – 3.06 (m, 1H), 2.95 – 2.84 (m, 1H), 2.84 – 2.71 (m, 1H), 2.48 (s, 3H), 2.42 (s, 3H), 2.03 (s, 1H); ^{19}F NMR (376 MHz, CDCl_3) δ -72.47 (d, J = 7.5 Hz); ^{13}C NMR (100 MHz, CDCl_3) δ 135.8, 134.2, 129.0, 128.9, 126.9 (q, J = 285 Hz), 126.8, 124.7, 124.3 (d, J = 3.3 Hz), 123.1,

120.8, 120.5, 118.6, 118.1, 113.8, 112.9, 112.5, 111.1, 60.4 (q, $J = 28$ Hz), 40.4, 22.1, 21.5, 16.6; IR (film): $\gamma = 3402, 2923, 2849, 1456, 1278, 1154, 1025, 995, 897, 784, 734 \text{ cm}^{-1}$; HRMS (EI-TOF): calcd for $C_{22}H_{20}F_3N_3$ 383.1609, found 383.1606.

(S)-(-)-6-chloro-1-(7-methyl-1H-indol-3-yl)-1-(trifluoromethyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole (3m): 14.5 mg, 72% yield; brown solid; m.p. 199–200°C; 90% ee (**3m**) was obtained with 98% ee after one recrystallization from EA-Hexane); HPLC analysis: Chiralpak AD-H (hexane/i-PrOH = 80/20, 0.8 mL/min), t_R (major) 11.006 min, t_R (minor) 16.171 min; $[\alpha]_D^{20} = -35.6$ (c 1.7, CH_2Cl_2); 1H NMR (400 MHz, $CDCl_3$) δ 8.09 (s, 1H), 8.05 (s, 1H), 7.58 (t, $J = 0.2$ Hz 1H), 7.21 (d, $J = 1.3$ Hz, 1H), 7.19 – 7.11 (m, 2H), 6.97 (d, $J = 6.6$ Hz, 1H), 6.93 – 6.82 (m, 2H), 3.40 – 3.29 (m, 1H), 3.20 – 3.09 (m, 1H), 2.94 – 2.85 (m, 1H), 2.85 – 2.75 (m, 1H), 2.45 (s, 3H), 2.02 (s, 1H); ^{19}F NMR (376 MHz, $CDCl_3$) δ -72.40 (s, 3F); ^{13}C NMR (100 MHz, $CDCl_3$) δ 135.8, 134.2, 130.4, 127.6, 126.8 (q, $J = 285$ Hz), 125.4, 124.6, 124.0 (d, $J = 2.9$ Hz), 123.2, 123.0, 120.9, 120.6, 118.5, 117.8, 113.5, 112.8, 112.4, 60.2 (q, $J = 28$ Hz), 40.3, 21.9, 16.5; IR (film): $\gamma = 3428, 2956, 2924, 2855, 1715, 1616, 1441, 1290, 1265, 1157, 1108, 1061, 997, 899, 799, 784, 741 \text{ cm}^{-1}$; HRMS (EI-TOF): calcd for $C_{21}H_{17}ClF_3N_3$ 403.1063, found 403.1064.

(S)-(-)-1-(7-methoxy-1H-indol-3-yl)-6-methyl-1-(trifluoromethyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole (3n): 17 mg, 86% yield; white solid; m.p. 196–197°C; 80% ee; HPLC analysis: Chiralpak AD-H (hexane/i-PrOH = 80/20, 0.8 mL/min), t_R (major) 17.159 min, t_R (minor) 22.534 min; $[\alpha]_D^{20} = -24.9$ (c 0.6, CH_2Cl_2); 1H NMR (400 MHz, $CDCl_3$) δ 8.46 (s, 1H), 7.94 (s, 1H), 7.40 (d, $J = 0.5$ Hz, 1H), 7.21 – 7.11 (m, 2H), 7.08 – 7.00 (m, 1H), 6.86 (t, $J = 8.0$ Hz, 1H), 6.76 (d, $J = 8.2$ Hz, 1H), 6.58 (d, $J = 7.6$ Hz, 1H), 3.91 (s, 3H), 3.38 – 3.27 (m, 1H), 3.19 – 3.10 (m, 1H), 2.97 – 2.86 (m, 1H), 2.86 – 2.75 (m, 1H), 2.48 (s, 3H), 2.18 (s, 1H); ^{19}F NMR (376 MHz, $CDCl_3$) δ -72.65 (s, 3F); ^{13}C NMR (100 MHz, $CDCl_3$) δ 146.1, 134.2, 129.0, 128.9, 127.0, 126.9 (q, $J = 285$ Hz), 126.8, 126.4, 124.3, 124.1 (d, $J = 2.2$ Hz), 120.9, 118.5, 113.9, 112.9, 112.5, 111.0, 102.2, 60.4 (q, $J = 28$ Hz), 55.3, 40.3, 22.1, 21.5; IR (film): $\gamma = 3408, 2955, 2925, 2853, 1724, 1626, 1578, 1459, 1411, 1377, 1263, 1154, 1051, 943, 900, 799, 783, 733 \text{ cm}^{-1}$; HRMS (EI-TOF): calcd for $C_{22}H_{20}F_3N_3O$ 399.1558, found 399.1552.

(S)-(-)-6-methoxy-1-(7-methoxy-1H-indol-3-yl)-1-(trifluoromethyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole (3o): 14.5 mg, 70% yield; white solid; m.p. 156–157°C; 80% ee; HPLC analysis: Chiralpak OOG-4457-EO (hexane/i-PrOH = 80/20, 0.8 mL/min), t_R (major) 9.556 min,

t_R (minor) 12.767 min; $[\alpha]_D^{20} = -40.2$ (c 1.2, CH_2Cl_2); ^1H NMR (400 MHz, CDCl_3) δ 8.49 (s, 1H), 7.94 (s, 1H), 7.17 (d, $J = 8.8$ Hz, 2H), 7.05 (d, $J = 2.4$ Hz, 1H), 6.92 – 6.82 (m, 2H), 6.75 (d, $J = 8.2$ Hz, 1H), 6.59 (d, $J = 7.7$ Hz, 1H), 3.91 (s, 3H), 3.88 (s, 3H), 3.40 – 3.27 (m, 1H), 3.22 – 3.10 (m, 1H), 2.96 – 2.86 (m, 1H), 2.86 – 2.76 (m, 1H), 1.71 (s, 1H); ^{19}F NMR (376 MHz, CDCl_3) δ -72.67 (s, 3F); ^{13}C NMR (100 MHz, CDCl_3) δ 154.14, 146.1, 131.0, 129.7, 127.0, 126.9 (q, $J = 285$ Hz), 126.9, 126.4, 124.2, 124.1 (d, $J = 2.4$ Hz), 120.9, 113.8, 112.9, 112.7, 112.1, 102.17 (s), 100.7, 60.4 (q, $J = 28$ Hz), 55.9, 55.3, 40.3, 22.1; IR (film): $\gamma = 3404, 2955, 2924, 2853, 1718, 1626, 1578, 1459, 1377, 1260, 1216, 1151, 1111, 939, 897, 783, 733 \text{ cm}^{-1}$; HRMS (EI-TOF): calcd for $\text{C}_{22}\text{H}_{20}\text{F}_3\text{N}_3\text{O}_2$ 415.1508, found 415.1505.

(S)-(-)-1-(7-chloro-1H-indol-3-yl)-6-methoxy-1-(trifluoromethyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole (3p): 14.4 mg, 69% yield; yellow solid; m.p. 111-112°C; 89% ee; HPLC analysis: Chiralpak AD-H (hexane/i-PrOH = 80/20, 0.8 mL/min), t_R (minor) 11.598 min, t_R (major) 17.434 min; $[\alpha]_D^{20} = -17.8$ (c 0.8, CH_2Cl_2); ^1H NMR (400 MHz, CDCl_3) δ 8.37 (s, 1H), 7.85 (s, 1H), 7.17 (s, 1H), 7.12 (d, $J = 8.8$ Hz, 1H), 7.07 (t, $J = 7.1$ Hz, 2H), 6.98 (d, $J = 2.3$ Hz, 1H), 6.86 – 6.76 (m, 2H), 3.81 (s, 3H), 3.36 – 3.21 (m, 1H), 3.12 – 3.01 (m, 1H), 2.90 – 2.79 (m, 1H), 2.79 – 2.68 (m, 1H), 1.90 (s, 1H); ^{19}F NMR (376 MHz, CDCl_3) δ -72.72 (s, 3F); ^{13}C NMR (100 MHz, CDCl_3) δ 154.2, 133.6, 131.0, 129.3, 126.8 (q, $J = 285$ Hz), 126.9, 126.7, 125.2 (d, $J = 2.4$ Hz), 121.9, 121.3, 119.3, 116.8, 114.7, 113.1, 112.8, 112.1, 100.7, 60.5 (q, $J = 28$ Hz), 55.9, 40.2, 22.1; IR (film): $\gamma = 3413, 2950, 2926, 2852, 1719, 1624, 1565, 1486, 1456, 1435, 1340, 1294, 1263, 1214, 1143, 1116, 1012, 913, 891, 832, 784, 737, 702 \text{ cm}^{-1}$; HRMS (EI-TOF): calcd for $\text{C}_{21}\text{H}_{17}\text{ClF}_3\text{N}_3\text{O}$ 419.1012, found 419.1015.

(S)-(-)-1-(7-chloro-1H-indol-3-yl)-6-methyl-1-(trifluoromethyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole (3q): 14 mg, 70% yield; yellow solid; m.p. 192-193°C; 90% ee; HPLC analysis: Chiralpak AD-H (hexane/i-PrOH = 80/20, 0.8 mL/min), t_R (major) 12.173 min, t_R (minor) 15.804 min; $[\alpha]_D^{20} = -44.8$ (c 0.4, CH_2Cl_2); ^1H NMR (400 MHz, CDCl_3) δ 8.40 (s, 1H), 7.92 (s, 1H), 7.41 (s, 1H), 7.27 – 7.17 (m, 2H), 7.15 (d, $J = 7.5$ Hz, 2H), 7.08 – 7.01 (m, 1H), 6.89 (t, $J = 7.9$ Hz, 1H), 3.41 – 3.28 (m, 1H), 3.19 – 3.06 (m, 1H), 2.97 – 2.86 (m, 1H), 2.86 – 2.75 (m, 1H), 2.48 (s, 3H), 2.04 (s, 1H); ^{19}F NMR (376 MHz, CDCl_3) δ -72.68 (s, 3F); ^{13}C NMR (100 MHz, CDCl_3) δ 134.2, 133.6, 129.1, 128.7, 126.7 (q, $J = 285$ Hz), 126.8, 126.7, 125.2 (d, $J = 2.5$ Hz), 124.5, 121.9, 121.3, 119.4, 118.6, 116.8, 114.7, 112.6, 111.1, 60.4 (q, $J = 28$ Hz), 40.3, 22.1, 21.5; IR (film): $\gamma = 3370,$


2922, 2846, 1563, 1435, 1339, 1277, 1155, 1084, 1016, 916, 891, 832, 783, 736 cm⁻¹; HRMS (EI-TOF): calcd for C₂₁H₁₇ClF₃N₃ 403.1063, found 403.1067.


(S)-(-)-6-chloro-1-(7-chloro-1H-indol-3-yl)-1-(trifluoromethyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole (3r): 13 mg, 61% yield; yellow solid; m.p. 223-224°C; 87% ee; HPLC analysis: Chiraldak AD-H (hexane/i-PrOH = 90/10, 0.8 mL/min), t_R (major) 29.595 min, t_R (minor) 40.966 min; [α]_D²⁰ = -20 (c 0.33, CH₂Cl₂); ¹H NMR (400 MHz, CDCl₃) δ 8.45 (s, 1H), 8.02 (s, 1H), 7.59 (d, J = 1.7 Hz, 1H), 7.31 (d, J = 1.3 Hz, 1H), 7.23 (d, J = 8.6 Hz, 1H), 7.20 – 7.14 (m, 2H), 7.06 (d, J = 8.1 Hz, 1H), 6.90 (t, J = 7.9 Hz, 1H), 3.44 – 3.32 (m, 1H), 3.24 – 3.12 (m, 1H), 2.97 – 2.78 (m, 2H), 1.83 (s, 3H); ¹⁹F NMR (376 MHz, CDCl₃) δ -72.61 (s, 3F); ¹³C NMR (100 MHz, CDCl₃) δ 134.2, 133.6, 130.1, 127.6, 126.6 (q, J = 285 Hz), 126.6, 125.6, 124.9 (d, J = 2.7 Hz), 123.2, 122.1, 121.4, 119.1, 118.6, 116.8, 114.4, 112.9, 112.4, 60.3 (m), 40.11 (q, J = 28 Hz), 21.9; IR (film): γ = 3461, 2950, 2917, 1617, 1557, 1435, 1302, 1261, 1224, 1163, 1138, 1100, 1011, 916, 795, 781, 738 cm⁻¹; HRMS (EI-TOF): calcd for C₂₀H₁₄Cl₂F₃N₃ 423.0517, found 423.0515.

4. References



1. F. X. Xu, D. Huang, C. Han, W. Shen, X. F. Lin, Y. G. Wang, *J. Org. Chem.*, **2010**, *75*, 8677-8680.
2. I. Čorić, S. Müller, B. List, *J. Am. Chem. Soc.*, **2010**, *132*, 17370.
3. M. Espinoza-Moraga, J. Caballero, F. Gaube, *Chem. Biol. Drug Des.*, **2012**, *79*, 594-599.
4. Mathieu P. Lalonde, Meredith A. McGowan, Naomi S. Rajapaksa, *J. Am. Chem. Soc.*, **2013**, *135*, 1891–1894.

5. Copies of NMR and HPLC for Compounds








1b ^1H NMR (400 MHz, CDCl_3)




1b ^{13}C NMR (100 MHz, CDCl_3)









1d ¹H NMR (400 MHz, CDCl₃)





1d ¹³C NMR (100 MHz, CDCl₃)







3a ^1H NMR (400 MHz, CDCl_3)





3a ^{13}C NMR (100 MHz, CDCl_3)








3a ^{19}F NMR (376 MHz, CDCl_3)





3b ^1H NMR (400 MHz, CDCl_3)









3c ^1H NMR (400 MHz, CDCl_3)





3c ^{13}C NMR (100 MHz, CDCl_3)










3d ^{13}C NMR (100 MHz, CDCl_3)





3d ^{19}F NMR (376 MHz, CDCl_3)
















3g ^1H NMR (400 MHz, CDCl_3)





3g ^{13}C NMR (100 MHz, CDCl_3)















3i ^{19}F NMR (376 MHz, CDCl_3)





3j ^1H NMR (400 MHz, CDCl_3)




136.217
134.224
130.386
128.182
127.605
125.418
125.330
125.050
124.373
124.348
123.074
122.710
120.527
120.159
118.506
112.978
112.747
112.367
111.401





3j ^{13}C NMR (100 MHz, CDCl_3)





3j ^{19}F NMR (376 MHz, CDCl_3)









3k ^{19}F NMR (376 MHz, CDCl_3)





3l ^1H NMR (400 MHz, CDCl_3)








3I ^{13}C NMR (100 MHz, CDCl_3)





3I ^{19}F NMR (376 MHz, CDCl_3)






3m ^1H NMR (400 MHz, CDCl_3)





3m ^{13}C NMR (100 MHz, CDCl_3)








3m ^{19}F NMR (376 MHz, CDCl_3)




3n ^1H NMR (400 MHz, CDCl_3)














3o ^{19}F NMR (376 MHz, CDCl_3)






3p ^1H NMR (400 MHz, CDCl_3)


















#	[min]		[min]	mAU	*s	[mAU]	%
1	13.105	VB	0.5597	2317.21069		61.81361	49.9288
2	18.983	VV	0.7396	2323.81763		46.78600	50.0712




#	[min]		[min]	mAU	*s	[mAU]	%
1	13.048	VB	0.5532	1.40429e4		377.68176	92.8904
2	18.997	MM	0.7234	1074.80066		24.76287	7.1096











#	[min]	[min]	mAU	*s	[mAU]	%
1	13.091	MM	0.7010	8715.50781	207.22331	49.4199
2	19.754	BB	0.8613	8920.13379	153.53711	50.5801







#	[min]	[min]	mAU	*s	[mAU]	%
1	13.049	MM	0.7527	1890.05725	41.84886	89.8572
2	19.619	MM	0.7006	213.34407	5.07493	10.1428
























































After one recrystallization from EA-Hexane





#	[min]		[min]	mAU	*s	[mAU]]	%
1	11.684	MM		0.5898	2.15124e4	607.88580		50.4958
2	15.230	MM		0.7661	2.10899e4	458.81381		49.5042

After one recrystallization from EA-Hexane

